Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial

Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial

Abstract Aims Treatment response to vericiguat, based on baseline N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) subgroups specified in the protocol, was evaluated in the heart failure (HF) VICTORIA trial population by post hoc analysis of combined lower three quartiles [Q1–Q3] vs. the upper q...

Full description

Bibliographic Details
Main Authors: Michele Senni, Jose Lopez‐Sendon, Alain Cohen‐Solal, Piotr Ponikowski, Richard Nkulikiyinka, Cecilia Freitas, Vanja Miodrag Vlajnic, Lothar Roessig, Burkert Pieske
Format: Article
Language:English
Published: Wiley 2022-12-01
Series:ESC Heart Failure
Subjects:
Heart failure
Heart failure with reduced ejection fraction
NT‐proBNP
Online Access:https://doi.org/10.1002/ehf2.14050

Internet

https://doi.org/10.1002/ehf2.14050

Similar Items